221 related articles for article (PubMed ID: 20203220)
1. Out of the darkness and into the light: bright field in situ hybridisation for delineation of ERBB2 (HER2) status in breast carcinoma.
Gruver AM; Peerwani Z; Tubbs RR
J Clin Pathol; 2010 Mar; 63(3):210-9. PubMed ID: 20203220
[TBL] [Abstract][Full Text] [Related]
2. Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists.
Dietel M; Ellis IO; Höfler H; Kreipe H; Moch H; Dankof A; Kölble K; Kristiansen G
Virchows Arch; 2007 Jul; 451(1):19-25. PubMed ID: 17562074
[TBL] [Abstract][Full Text] [Related]
3. Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome.
Francis GD; Jones MA; Beadle GF; Stein SR
Diagn Mol Pathol; 2009 Jun; 18(2):88-95. PubMed ID: 19430296
[TBL] [Abstract][Full Text] [Related]
4. Silver in situ hybridization (SISH) for determination of HER2 gene status in breast carcinoma: comparison with FISH and assessment of interobserver reproducibility.
Papouchado BG; Myles J; Lloyd RV; Stoler M; Oliveira AM; Downs-Kelly E; Morey A; Bilous M; Nagle R; Prescott N; Wang L; Dragovich L; McElhinny A; Garcia CF; Ranger-Moore J; Free H; Powell W; Loftus M; Pettay J; Gaire F; Roberts C; Dietel M; Roche P; Grogan T; Tubbs R
Am J Surg Pathol; 2010 Jun; 34(6):767-76. PubMed ID: 20421783
[TBL] [Abstract][Full Text] [Related]
5. Assessment of ErbB2 (Her2) in oesophageal adenocarcinomas: summary of a revised immunohistochemical evaluation system, bright field double in situ hybridisation and fluorescence in situ hybridisation.
Langer R; Rauser S; Feith M; Nährig JM; Feuchtinger A; Friess H; Höfler H; Walch A
Mod Pathol; 2011 Jul; 24(7):908-16. PubMed ID: 21516080
[TBL] [Abstract][Full Text] [Related]
6. Prospective multi-centre study to validate chromogenic in situ hybridisation for the assessment of HER2 gene amplification in specimens from adjuvant and metastatic breast cancer patients.
Riethdorf S; Hoegel B; John B; Ott G; Fritz P; Thon S; Loening T; Pantel K
J Cancer Res Clin Oncol; 2011 Feb; 137(2):261-9. PubMed ID: 20396915
[TBL] [Abstract][Full Text] [Related]
7. [Assessment of HER2 gene amplification in breast cancer: a comparison of dual-color in-situ hybridization and fluorescence in-situ hybridization].
Xu Y; Yang W; Yang F; Lu Y; Cai X; Zhou X
Zhonghua Bing Li Xue Za Zhi; 2014 Apr; 43(4):226-30. PubMed ID: 24915811
[TBL] [Abstract][Full Text] [Related]
8. Emerging technologies for assessing HER2 amplification.
Penault-Llorca F; Bilous M; Dowsett M; Hanna W; Osamura RY; Rüschoff J; van de Vijver M
Am J Clin Pathol; 2009 Oct; 132(4):539-48. PubMed ID: 19762531
[TBL] [Abstract][Full Text] [Related]
9. Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer.
Arnould L; Denoux Y; MacGrogan G; Penault-Llorca F; Fiche M; Treilleux I; Mathieu MC; Vincent-Salomon A; Vilain MO; Couturier J
Br J Cancer; 2003 May; 88(10):1587-91. PubMed ID: 12771927
[TBL] [Abstract][Full Text] [Related]
10. Dual-color dual-hapten in situ hybridization (D-DISH) - Comparison with fluorescence in situ hybridization (FISH) for HER2/neu testing in breast cancer.
Gajaria PK; Tambe S; Pai T; Patil A; Desai SB; Shet TM
Indian J Pathol Microbiol; 2020; 63(2):194-199. PubMed ID: 32317514
[TBL] [Abstract][Full Text] [Related]
11. Next-generation assessment of human epidermal growth factor receptor 2 gene (ERBB2) amplification status in invasive breast carcinoma: a focus on Group 4 by use of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 testing guideline.
Hoda RS; Bowman AS; Zehir A; Razavi P; Brogi E; Ladanyi M; Arcila ME; Wen HY; Ross DS
Histopathology; 2021 Mar; 78(4):498-507. PubMed ID: 32841416
[TBL] [Abstract][Full Text] [Related]
12. Bright-field HER2 dual in situ hybridization (DISH) assay vs fluorescence in situ hybridization (FISH): focused study of immunohistochemical 2+ cases.
Gao FF; Dabbs DJ; Cooper KL; Bhargava R
Am J Clin Pathol; 2014 Jan; 141(1):102-10. PubMed ID: 24343743
[TBL] [Abstract][Full Text] [Related]
13. Comparison of fluorescence in-situ hybridisation with dual-colour in-situ hybridisation for assessment of HER2 gene amplification of breast cancer in Hong Kong.
Tang SM; Soong IS; Luk MY; Suen DT; Hioe F; Man EP; Tsun OK; Khoo US
Hong Kong Med J; 2016 Apr; 22(2):144-51. PubMed ID: 26823385
[TBL] [Abstract][Full Text] [Related]
14. Chromogenic in situ hybridisation testing for HER2 gene amplification in breast cancer produces highly reproducible results concordant with fluorescence in situ hybridisation and immunohistochemistry.
Bilous M; Morey A; Armes J; Cummings M; Francis G
Pathology; 2006 Apr; 38(2):120-4. PubMed ID: 16581651
[TBL] [Abstract][Full Text] [Related]
15. HER2 assessment by silver in situ hybridization: where are we now?
Sanguedolce F; Bufo P
Expert Rev Mol Diagn; 2015 Mar; 15(3):385-98. PubMed ID: 25578771
[TBL] [Abstract][Full Text] [Related]
16. HER2 assessment by bright-field dual in situ hybridization in cell blocks of recurrent and metastatic breast carcinoma.
Edelweiss M; Sebastiao APM; Oen H; Kracun M; Serrette R; Ross DS
Cancer Cytopathol; 2019 Nov; 127(11):684-690. PubMed ID: 31544361
[TBL] [Abstract][Full Text] [Related]
17. Determination of HER2 amplification in primary breast cancer using dual-colour chromogenic in situ hybridization is comparable to fluorescence in situ hybridization: a European multicentre study involving 168 specimens.
García-Caballero T; Grabau D; Green AR; Gregory J; Schad A; Kohlwes E; Ellis IO; Watts S; Mollerup J
Histopathology; 2010 Mar; 56(4):472-80. PubMed ID: 20459554
[TBL] [Abstract][Full Text] [Related]
18. Her2 amplification: correlation of chromogenic in situ hybridization with immunohistochemistry and fluorescence in situ hybridization.
Wixom CR; Albers EA; Weidner N
Appl Immunohistochem Mol Morphol; 2004 Sep; 12(3):248-51. PubMed ID: 15551739
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of HER2 gene amplification in invasive breast cancer using a dual-color chromogenic in situ hybridization (dual CISH).
Kato N; Itoh H; Serizawa A; Hatanaka Y; Umemura S; Osamura RY
Pathol Int; 2010 Jul; 60(7):510-5. PubMed ID: 20594272
[TBL] [Abstract][Full Text] [Related]
20. Validation and workflow optimization of human epidermal growth factor receptor 2 testing using INFORM HER2 dual-color in situ hybridization.
Lim SJ; Cantillep A; Carpenter PM
Hum Pathol; 2013 Nov; 44(11):2590-6. PubMed ID: 24075600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
